- Email:
AAV Preparation Service for Neural Circuitry Research
Introduction
AAV vectors are essential for modern connectomics due to their high safety and stable long-term expression. Creative Biolabs offers professional AAV preparation services with engineered capsids for neural circuit tracing and manipulation. The service provides high-titer, cell-type-specific AAV vectors suitable for optogenetics and calcium imaging. It enables precise targeting in hard-to-transduce brain regions, supporting high-quality neuroscience research and preclinical development.
Discover How We Can Help - Request a Consultation
AAV Preparation Service for Neural Circuitry Research
AAV vectors are widely favored in neuroscience and gene therapy for their high safety profile and stable long-term expression in post-mitotic cells such as neurons. They can efficiently transduce various brain regions and cell types with low immunogenicity and minimal inflammatory response. With multiple natural and engineered serotypes available, AAV enables flexible, cell-type-specific gene delivery. These features make it one of the most reliable tools for neural circuit tracing, optogenetics, and preclinical gene therapy development.
Fig.1 Uses of CNS organoids in AAV-mediated gene therapy.1
Key Advantages
-
Precise Neural Targeting
Neuron-specific promoters and engineered capsids ensure highly specific expression in targeted neuronal subtypes and brain circuits, minimizing off-target effects. -
Stringent Quality Control
Strict assays are performed for viral titer (≥1013 GC/mL), purity (>95%), empty capsid ratio (<10%), endotoxin and mycoplasma contamination, guaranteeing stable performance in vitro and in vivo. -
High & Sustained Expression
Self-complementary AAV (scAAV) is available for rapid and robust expression. AAV exhibits low immunogenicity and supports long-term stable expression in post-mitotic neurons. -
Flexible & Efficient Customization
Custom solutions are provided for basic vectors to advanced neural circuit tools with short turnaround times, supporting cutting-edge studies including optogenetics, chemogenetics, and axonal tracing.
Main Applications
-
Neural Circuit Tracing
Labeling neuronal projections with fluorescent or optogenetic probes to map brain-wide connectivity and functional networks. -
Neuronal Activity Manipulation
Delivery of photosensitive proteins, DREADDs, and other effectors for precise, reversible modulation of neuronal activity. -
Neurological Disease Modeling
Overexpression or knockdown of disease-related genes (APP, α-synuclein, etc.) to establish models of Alzheimer's, Parkinson's, and other neurodegenerative disorders. -
Gene Therapy Development
Delivery of therapeutic genes or CRISPR-editing systems for preclinical research on genetic and degenerative brain diseases. -
Cell-Type-Specific Genetic Control
Combined with the Cre-LoxP system to achieve targeted gene editing and functional analysis in defined neuronal populations.
Workflow
Our streamlined process ensures that every viral preparation meets the rigorous demands of in vivo neuroscience research.
What We Can Offer
Creative Biolabs provides a premium, industrial-grade AAV production platform specifically optimized for the rigorous demands of systems neuroscience. Our advantages include:
End-to-End Scalability
One-stop AAV production service spanning from laboratory-scale pilot studies to large-scale industrial batches, supporting both basic research and clinical-stage development.
Customized Engineering
Full customization of vector components, including codon optimization of your transgene to maximize expression in specific neuronal subtypes and the design of hybrid capsids for unique tropism.
High-Capacity Production
Utilization of large-scale suspension culture systems and high-volume bioreactors to ensure a consistent supply for multi-center studies or large-animal (NHP) trials.
Precision Quality Control
Implementation of Quality-by-Design (QbD) and Process Analytical Techniques (PAT) to guarantee the stability, purity, and high full-to-empty capsid ratios of every preparation.
Advanced Aseptic Verification
Strict aseptic protocols and Hazard Analysis Critical Control Point (HACCP) approaches throughout the manufacturing process to eliminate contaminants that could interfere with neural tissue health.
Stability Guarantee
Rigorous assessment of strain origin and vector stability in cell banks to ensure reproducible results across different experimental cohorts and long-term studies.
GMP-Certified Excellence
High-standard production environments that follow the basic principles of Good Manufacturing Practice (GMP), ensuring your data is ready for regulatory scrutiny.
Experience the Creative Biolabs Advantage - Get a Quote Today
Customer Reviews
FAQs
Q1: How do you ensure the AAV doesn't spread beyond the intended circuit?
A: We utilize cell-type-specific promoters and intersectional logic. This ensures that even if the virus spreads physically, the gene is only expressed in cells containing the specific recombinase (like Cre or Flp).
Q2: Can I use your AAVs for systemic administration (IV injection)?
A: Yes, we offer blood-brain barrier (BBB)-crossing serotypes such as AAV9, which are specifically designed for widespread CNS transduction following systemic delivery.
Q3: What is the minimum titer you provide for neuroscience applications?
A: For neural circuitry research, we typically aim for a minimum of 1012 to 1013 vg/mL, as high titers are essential for efficient axonal transport and trans-synaptic labeling.
Q4: How should I store the AAV upon arrival?
A: AAV should be stored at -80°C. We recommend minimizing freeze-thaw cycles by creating small-volume aliquots upon first use to maintain maximum infectivity.
Q5: Are your AAV services compatible with CRISPR/Cas9 systems?
A: Yes. We have extensive experience packaging large or split-intein Cas9 systems and gRNA arrays into AAV for targeted genome editing within specific neural circuits.
Contact Our Team for More Information and to Discuss Your Project
Reference
- Kaiser, Vivienne M., and Anai Gonzalez-Cordero. "Organoids–the future of pre-clinical development of AAV gene therapy for CNS disorders." Gene Therapy (2025): 1-13. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41434-025-00527-8.
For Research Use Only. Not For Clinical Use.